Shield AI Agrees to Acquire Echodyne for $5.3B and Raises $2.5B, Series H at $28.8B

Shield AI has entered a definitive agreement to acquire Echodyne in a transaction valued at $5.3 billion, and it is raising $2.5 billion to support the deal, the company said in its November 5 release. The package includes $1 billion of Series H funding at a $28.8 billion post-money valuation. Closing is expected in early 2027.

The numbers

• $5.3 billion is the transaction value. Shield said $4.8 billion will be paid and issued at closing, and up to $500 million more depends on Echodyne hitting agreed performance targets. Bloomberg described the $4.8 billion as cash and equity.
• The $2.5 billion breaks into three instruments. $1 billion is the Series H at a $28.8 billion post-money valuation. $1 billion is structured equity from funds managed by Blackstone. $500 million is debt financing led by JPMorgan Chase Bank, N.A., as sole arranger.
• Disruptive and Innovation X Capital are co-leading the Series H. Advent, the Strategic Investment Group of JPMorganChase's Security and Resiliency Initiative, Snowpoint Ventures, Apandion, Center15 Capital, and others are participating. Shield said Series H proceeds will principally fund the acquisition.
• Bloomberg reported that Shield raised $2 billion at a $12.7 billion value in March, and called $28.8 billion more than double that March figure.
• Shield said both companies expect triple-digit revenue growth this fiscal year.

What Echodyne adds

Echodyne designs compact solid-state radars with its Metamaterials Electronically Scanned Array, which it calls MESA. Shield said those radars are built into hundreds of counter-drone and security systems used by defense, government, and commercial customers in more than 40 countries. In September, Echodyne received a contract with a $250 million ceiling from Joint Interagency Task Force 401 to supply counter-drone radar to U.S. and allied forces.

Shield said the radars are integrated onto remote weapon stations, high-energy lasers, and high-power microwave systems, and that they cue interceptors toward incoming drones. Civilian operators use the same radars to protect stadiums and airports, and to let police and fire departments fly drones in shared airspace.

After closing, Echodyne's team stays in place, in Kirkland, Washington. Frankenberg will report to Steele and keep responsibility for products, manufacturing, and customers. MESA radars remain available as standalone products. Shield said Echodyne recently opened an 86,350-square-foot plant, a $40 million investment, able to produce about 30,000 radars a year. In September, Shield named Washington the production home for X-BAT.

"The acquisition of Echodyne dramatically accelerates our efforts to meet growing customer demand for multi-mission capabilities, provides increased access to a rapidly expanding counter-drone industry, and further diversifies our revenue streams."

Gary Steele, chief executive of Shield AI, in the November 5 release

"Shield shares our view that autonomous systems can only act on what they can sense, and superior sensors lead to superior systems and outcomes."

Eben Frankenberg, chief executive of Echodyne, in the November 5 release

Where this sits in Shield

Shield, founded in 2015, sells Hivemind autonomy software, the V-BAT and X-BAT aircraft, and Aechelon simulation tools. Steele described the company as three units, autonomy software, autonomous systems, and mission systems. The Echodyne deal is the mission systems buildout.

Breaking Defense reported that a Shield spokesperson said there are no planned workforce cuts and that Echodyne employees will not have to relocate. The spokesperson said Shield is not announcing specific aircraft integrations, and that separate radar work with RTX on X-BAT is unchanged. Breaking Defense also wrote that V-BAT came from the 2021 purchase of Martin UAV, and that Shield closed its purchase of Aechelon earlier this year.

What we are watching

Shield has signed the agreement. Closing still depends on regulatory approvals and other customary conditions, and the company pointed to early 2027. The $28.8 billion figure is the post-money valuation on the $1 billion Series H alone. The release leaves the cash-versus-stock split inside the $4.8 billion unspecified, and it leaves Echodyne's revenue undisclosed. The next hard date is the close.